tbuckley/cabot-search huggingface dataset:
Cimetidine for ever (and ever and ever...)?
Journal: BMJ (1978)

Cimetidine for ever (and ever and ever ...)?The histamine H-2 antagonist cimetidine was released for general use in Britain 18 months ago.By then a mass of published work had shown it and its toxic predecessor metiamide to be such potent suppressors of gastric acid secretion that their effects on upper gastrointestinal function and disease were likely to be revolutionary.Today we have no doubt about the value of cimetidine for healing acute duodenal ulcers and for relieving symptoms, compared with a placebo.1 2 On the other hand, compared with "intensive" antacid treatment, there is little difference in the effects on diminished gastric acid3 and therapeutic benefit.4Nevertheless, taking 210 ml of daily antacid is less convenient and more expensive and will provoke diarrhoea.3 4For the acute ulcer cimetidine is clearly the better choice.What remains to be seen is how long its effects will last and how the clinician should best use the drug in managing patients with chronic ulcers.Early experience with metiamide5 suggested that prolonged treatment at full dosage would keep symptoms at bay.Treat- ment with cimetidine twice daily for a year prevents endoscopic recurrence," and, since the drug is most potent in suppressing
Improvement of Glycemic Control, Triglycerides, and HDL Cholesterol Levels With Muraglitazar, a Dual ( / ) Peroxisome Proliferator-Activated Receptor Activator, in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: A double-blind, randomized, pioglitazone-comparative study
Authors: D. M. Kendall
Journal: Diabetes Care (2006)

OBJECTIVE—We sought to evaluate the effects of muraglitazar, a dual (α/γ) peroxisome proliferator–activated receptor (PPAR) activator within the new glitazar class, on hyperglycemia and lipid abnormalities.
State Boards of Registration.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Interferon increases extracellular matrix degradation and plasminogen activator activity in livers from cirrhotic rats L . aDepartamento de Gastroenterolog�a, Instituto Nacional de la Nutrici�n Salvador Zubir�n, M�xico, D.F. and bDepartamento de Farmacolog�a y Toxicolog�a, Centro de Investigaci�n y de Estudios Avanzados del I.P.N., M�xico, D.F., M�xico
Journal: Hepatology (1995)
Neurodegenerative Mouse
Authors: Tracy Hampton
Journal: JAMA (2007)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Appointments
Authors: K. Smigel
Journal: JNCI Journal of the National Cancer Institute (1988)

Journal Article Appointments Get access Kara Smigel Kara Smigel Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 80, Issue 15, 5 October 1988, Page 1191, https://doi.org/10.1093/jnci/80.15.1191 Published: 05 October 1988
Fasting and the precipitation of labor. The Yom Kippur effect
Authors: M. Kaplan
Journal: JAMA (1983)

We analyzed the effect of a 24-hour total food and water fast on the spontaneous onset of labor by studying the effect of the fast of Yom Kippur on Jewish pregnant women in Jerusalem. The mean baseline number of deliveries for our study period was 11.9 and 12.0 for 1981 and 1982, respectively. The number of deliveries on Yom Kippur was not significantly different from the mean. However, the number of deliveries for the 24-hour period after termination of the fast was 22 and 26 for 1981 and 1982, respectively. This difference attained statistical significance. While the clinical implications are not yet clear, a special risk may exist for women with a tendency toward early delivery should they undertake a 24-hour fast. (<i>JAMA</i>1983;250:1317-1318)
Abstract 2268: Tenascin C as an effector of prostate cancer derived bone metastasis
Authors: Rebeca San Martin, David R. Rowley, Kenneth J. Pienta
Journal: Cancer Research (2015)

Abstract The stroma plays a key role in maintenance of tissue homeostasis. A reactive stroma evolves early in the progression of prostate cancer. One way reactive stroma remodels the microenvironment is by deposition of tenascin-C. Tenascin-C is an extracellular matrix protein that is expressed during development and is critical for neuronal patterning and osteogenesis. In contrast, expression of tenascin C in adult tissues is limited and is restricted to regions of wound repair, tissue remodeling and pathological conditions, such as cancer. To assess whether the bone exhibits a reactive tissue phenotype in the context of metastasis, human prostate cancer metastasis tissue arrays were evaluated using immunohistochemistry and spectral deconvolution. This work identified a tenascin-C expression pattern at trabeculae-associated metastatic sites, suggesting the evolution of a reactive endosteum. In order to evaluate the mechanisms involved, we developed an in vitro 3D osteogenic organoid, using human mesenchymal stem cells induced to osteoblastic differentiation, which exhibits a reactive endosteum phenotype. Co-culture with the metastatic prostate cancer cell line VCaP showed preferential binding at sites high in tenascin C deposition. Also, metastatic cells were capable of adherence to purified tenascin C in vitro, forming 3D colonies. We have identified α9β1 integrin as a mediator of prostate cancer cell adhesion to tenascin C-rich surfaces. Preliminary data has also identified signaling through WNK1 and STAT6 as additional candidate mechanisms that mediate tenascin-C induced biology in prostate cancer cells that are metastatic to bone surfaces. These studies characterize a reactive endosteum phenotype at sites of metastatic prostate cancer foci and suggest that elevated tenascin-C at these sites mediates the adhesive and other biological properties of cancer cells. This study will help provide data from which to develop novel therapeutic approaches to treat metastatic disease. Citation Format: Rebeca San Martin, David R. Rowley, Kenneth J. Pienta. Tenascin C as an effector of prostate cancer derived bone metastasis. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2268. doi:10.1158/1538-7445.AM2015-2268
A Nonsteroidal Anti-inflammatory Agent
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PLoS Medicine
Authors: Paul Garner, Helen Smith
Journal: BMJ (2004)

An open access, online journal from the Public Library of Science; first issue October 2004 ISSN 1549 1277 www.plosmedicine.org Rating: ![Graphic][1]</img>![Graphic][2]</img>![Graphic][3]</img>![Graphic][4]</img> “ P rescription for a healthy journal: take monthly, at no cost; reaches six billion.” These are the heady first words written by the editors of PLoS Medicine , which hit our screens for the first time this month. This first issue, with its fascinating variety of commentary, essays, and original research, is about as good as it gets for a global medical journal. With science and research at the core of the journal, the editors have tackled head on … [1]: /embed/inline-graphic-1.gif [2]: /embed/inline-graphic-2.gif [3]: /embed/inline-graphic-3.gif [4]: /embed/inline-graphic-4.gif
Issue Information ‐ TOC
Authors: Bowen Ke, Mao Tian, Jingjing Li, Bo Liu, Gu He, Min Yan, Chunli Wang, Mengying Yang, Mengying Tong, Zijie Long, Bing Liu, Fei Peng, Lingzhi Xu, Yan Zhang, Dapeng Liang, Haixin Lei, Sen Subrata, Keith Kelley, -F Lam, Bilian Jin, Quentin Liu, Pascal Gervois, Esther Wolfs, Jessica Ratajczak, Y Örg Dillen, Tim Vangansewinkel, Petra Hilkens, Annelies Bronckaers, Ivo Lambrichts, Tom Struys, Annelies Stevaert, Lieve Naesens, Joe Tomaszewski
Journal: Medicinal Research Reviews (2016)

The journal publishes timely critical reviews of topics related to medicinal research, broadly defined, to which the authors have made significant contributions.Appropriate topics include, but are not limited to, the underlying pathophysiology of important diseases and disease vectors; therapeutic approaches to the treatment of various diseases; the properties of molecular targets for therapeutic agents; important new methodologies facilitating the search for therapies; genomics and proteomics; structure-activity correlations of drug series; the development of new imaging and diagnostic tools; drug metabolism; drug delivery; and chemical, pharmacological, pharmacokinetic, pharmacodynamic, and clinical characteristics of important drugs.Reviews are mainly solicited by the editors; however, voluntary contributions are also encouraged.In the latter case, potential authors are asked to contact the Editor-in-Chief with an outline before beginning to write in order to avoid duplication of effort and to ensure suitability of the topic and the level of coverage.
446PD Second-line afatinib vs erlotinib for patients with squamous cell carcinoma of the lung in LUX-Lung 8: analysis of tumor and serum biomarkers
Authors: K.H. Lee, J-C. Soria, E. Felip, M. Cobo, S. Lu, K. Syrigos, E. Goker, V. Georgoulias, W. Li, S. Guclu, D. Isla, A. Ardizzoni, S.M. Gadgeel, N. Dupuis, N.J. Gibson, N. Krämer, C. Bühnemann, F. Solca, E. Ehrnrooth, G. Goss
Journal: Annals of Oncology (2016)
Factor VIII
Authors: HARVEY R. GRALNICK
Journal: Annals of Internal Medicine (1977)

Hemophilia and von Willebrand disease are two congenital hemorrhagic disorders associated with a deficiency of factor VIII activity. Newly developed assays for the factor VIII/von Willebrand factor antigen and for the ristocetin cofactor (von Willebrand factor activity) have enabled investigators to better understand the role of the protein in coagulation and its interaction with platelets. A major area of controversy concerns the structure of the protein. One group thinks the factor VIII/von Willebrand factor consists of a single protein that possesses both procoagulant and von Willebrand factor activity. Others believe it is a complex of one large protein with von Willebrand factor and antigen activity and a small protein possessing procoagulant activity. Despite our greater knowledge of the biochemical abnormalities in these disorders, we still do not know why some patients with hemophilia A develop inhibitors. New goals for treatment of patients with hemophilia include prevention of the crippling arthopathy associated with it, improved psychosocial adjustments, and recognition and care of secondary manifestations of the disease or effects of therapy.
Cancer Rehabilitation
Authors: Richard F. Harvey
Journal: JAMA (1982)

Information about comprehensive rehabilitation for patients with cancer is limited. Only a few descriptions of existing models are found in the literature. A survey questionnaire concerning the description and operation of cancer rehabilitation programs was developed and mailed to identified programs in 95 facilities throughout the country. Thirty-six facilities responded with data appropriate for analysis of their method of organization, treatment approaches, team composition, program emphasis, evaluation procedures, and program results. A literature and survey analysis provide support for an interdisciplinary team approach for rehabilitation of cancer patients disabled by the disease or its treatment. In addition, the survey shows favorable acceptance and success of cancer rehabilitation programs, especially in community hospital settings. (<i>JAMA</i>1982;247:2127-2131)
RBRVS: objections to Maloney, I
Authors: W. Hsiao
Journal: JAMA (1992)

DR MALONEY'S<sup>1</sup><i>JAMA</i>article entitled "A Critical Analysis of the Resource-Based Relative Value Scale" is a good illustration of the aphorism that statistics do not lie, but people misuse them. Dr Maloney divided the annual net income by the total number of hours worked for various specialties and concluded that, under the resource-based relative value scale (RBRVS), surgical services measured on an hourly basis would be paid less than evaluation and management (E/M) services. Dr Maloney obtained this erroneous conclusion because he used incorrect data and employed seriously flawed methods. He then made unwarranted generalizations and presented a global assessment of the RBRVS that is wholly incorrect. We concur with the critique of Dr Maloney's methods and data presented by Radecki et al.<sup>2</sup>The data from Mendenhall's<sup>3</sup>study regarding weekly hours worked, on which many of Dr Maloney's calculations are based, were gathered in the late 1970s
Journal of Investigative Dermatology, Baltimore
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Multivesicular stellate cells in primary biliary cirrhosis
Authors: R Cameron
Journal: Hepatology (1997)

Stellate cells have only recently received attention in patients with primary biliary cirrhosis (PBC). We used electron microscopy and morphometry to perform a qualitative and quantitative examination of lipid-storing activity of stellate cells in liver biopsies of 26 patients with noncirrhotic and cirrhotic PBC. Parallel with this study, a comparative analysis of the morphology of stellate cells in 51 patients with livers of normal histology was performed. There was a marked increase in the total number of lipid vesicles in stellate cells in all PBC patients when compared to livers with normal histology. Multiple multivesicular stellate cells were seen in the livers of 21 out of 26 patients with PBC. There were 11 to 28 lipid vesicles per multivesicular stellate cell from 1 μmol/L to 5 μmol/L in diameter per lipid vesicle. Hepatocytes showed little or no steatosis in 24 out of 26 (92%) PBC patients. Multivesicular stellate cells were not seen in female patients with normal liver histology. These results suggest that there is an alteration in hepatic lipid-storage that involves stellate cells in PBC, which could be an early manifestation of this disease. Its significance remains to be determined.
The first strictly full-time professor of medicine in an American medical school: Hopkins, not Michigan
Authors: A. B. Weisse
Journal: JAMA (1991)

<h3>In Reply.</h3> —Dr Weisse's claim that George Dock of the University of Michigan was the first full-time professor of medicine in an American medical school is not supported by the contemporary printed and manuscript evidence. The problem, I believe, stems from the multiple definitions that have been applied to the term "full-time." In my essay, I pointed out that I was discussing the original<i>strict</i>full-time system that prohibited clinical professors from earning any income from private practice. This plan was first instituted at Johns Hopkins in 1913, as was detailed in my article. Horace Davenport has written extensively on George Dock and the University of Michigan. His writings indicate that Dock had a private practice while he was professor of medicine at Michigan.<sup>1</sup>Davenport acknowledged that Michigan did not adopt the strict full-time system before Johns Hopkins. He wrote: "One reason Michigan had trouble finding a successor to
Oral administration of specific antigens to allergy-prone infant dogs induces IL-10 and TGF-? expression and prevents allergy in adult life
Authors: Barbara Zemann, Christoph Schwaerzler, Monika Griot-Wenk, Marijke Nefzger, Peter Mayer, Heinz Schneider, Alain de Weck, José M Carballido, Ekke Liehl
Journal: Journal of Allergy and Clinical Immunology (2003)
Reply to Thorsten Derlin, Christoph-A. von Klot, and Katja Hueper's Letter to the Editor re: Sungmin Woo, Chong Hyun Suh, Sang Youn Kim, Jeong Yeon Cho, Seung Hyup Kim. Diagnostic Performance of Magnetic Resonance Imaging for the Detection of Bone Metastasis in Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.03.042
Authors: Sungmin Woo, Chong Hyun Suh, Sang Youn Kim
Journal: European Urology (2017)
News and Notices
Authors: Eli Sprecher, John Ingram, Penny Lovat, Sara Brown, Tamar Nijsten, David Burden, Loes Hollestein
Journal: British Journal of Dermatology (2015)

Journal Article News and Notices Get access Eli Sprecher, Eli Sprecher Department of Dermatology and Laboratory of Molecular Medicine Tel Aviv Sourasky Medical Center Tel Aviv Israel Search for other works by this author on: Oxford Academic Google Scholar John Ingram, John Ingram Department of Dermatology & Wound Healing University Hospital of Wales Cardiff University Cardiff U.K Search for other works by this author on: Oxford Academic Google Scholar Penny Lovat, MPhil, PhD, Penny Lovat, MPhil, PhD Institute of Cellular Medicine The Medical School Newcastle University Framlington Place Newcastle upon Tyne NE2 4HH U.K Search for other works by this author on: Oxford Academic Google Scholar Sara Brown, Sara Brown Dermatology & Genetic Medicine, Division of Cancer Research Medical Research Institute Ninewells Hospital and Medical School University of Dundee Dundee DD1 9SY U.K Search for other works by this author on: Oxford Academic Google Scholar Tamar Nijsten, Tamar Nijsten Department of Dermatology Erasmus Medical Center Rotterdam The Netherlands Search for other works by this author on: Oxford Academic Google Scholar David Burden, David Burden Department of Deermatology Western Infirmary Glasgow U.K Search for other works by this author on: Oxford Academic Google Scholar Loes Hollestein Loes Hollestein Erasmus MC University Medical Center Rotterdam Rotterdam The Netherlands Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 172, Issue 3, 1 March 2015, Pages 839–840, https://doi.org/10.1111/bjd.13731 Published: 01 March 2015
Erratum: RIP1 is required for IAP inhibitor-mediated sensitization of childhood acute leukemia cells to chemotherapy-induced apoptosis
Authors: S Loeder, M Schirmer, H Schoeneberger, S Cristofanon, J Leibacher, N Vanlangenakker, M J M Bertrand, P Vandenabeele, I Jeremias, K-M Debatin, S Fulda
Journal: Leukemia (2012)
Ninth European Symposium on Hormones and Cell Regulation
Journal: JNCI Journal of the National Cancer Institute (1984)

Journal Article Ninth European Symposium on Hormones and Cell Regulation Get access JNCI: Journal of the National Cancer Institute, Volume 72, Issue 4, April 1984, Page 964, https://doi.org/10.1093/jnci/72.4.964 Published: 01 April 1984